MCID: RNV001
MIFTS: 49

Renovascular Hypertension

Categories: Cardiovascular diseases, Nephrological diseases

Aliases & Classifications for Renovascular Hypertension

MalaCards integrated aliases for Renovascular Hypertension:

Name: Renovascular Hypertension 12 6 15 17 32
Hypertension, Renovascular 43 71
Hypertension Renovascular 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1591
MeSH 43 D006978
NCIt 49 C85044
ICD10 32 I15.0
UMLS 71 C0020545

Summaries for Renovascular Hypertension

MalaCards based summary : Renovascular Hypertension, also known as hypertension, renovascular, is related to malignant renovascular hypertension and renal artery obstruction. An important gene associated with Renovascular Hypertension is REN (Renin), and among its related pathways/superpathways are Pathways in cancer and Development Angiotensin activation of ERK. The drugs Aspirin and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and heart, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renovascular Hypertension

Diseases in the Renovascular Hypertension family:

Benign Renovascular Hypertension Malignant Renovascular Hypertension

Diseases related to Renovascular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 352)
# Related Disease Score Top Affiliating Genes
1 malignant renovascular hypertension 33.9 REN EDN1 AGTR1
2 renal artery obstruction 31.2 REN ACE
3 fibromuscular dysplasia 31.0 YY1AP1 REN AGTR1 ACE
4 arteriosclerosis 31.0 NOS3 HMOX1 EDN1 ACE
5 renal hypertension 31.0 REN NPPB NOS3 EDN1 AGTR1 ADM
6 acute kidney failure 30.9 REN NPPA LCN2 CAT
7 carotid stenosis 30.7 REN NOS3 ACE
8 hypertension, diastolic 30.7 REN NPPA ACE
9 multicystic dysplastic kidney 30.6 REN PKD1
10 kidney hypertrophy 30.4 REN NOS3 ACE
11 retinal vascular disease 30.4 REN NOS3 EDN1 ACE
12 renal artery disease 30.4 REN NPPA NOS3 AGTR1 ACE
13 generalized atherosclerosis 30.3 REN ACE
14 hypertensive retinopathy 30.3 REN AGTR1 ACE
15 sleep disorder 30.3 REN EDN1 ACE
16 hypertensive encephalopathy 30.3 REN AGTR1 ACE
17 limb ischemia 30.2 NOS3 EDN1 ACE
18 aortic valve insufficiency 30.1 REN NPPB ACE
19 cerebral arterial disease 30.1 PKD1 NOS3 NF1 EDN1
20 atrial standstill 1 30.0 NPPB NPPA ACE
21 atherosclerosis susceptibility 30.0 NOS3 EDN1 AGTR1 ACE
22 sexual disorder 30.0 NOS3 NOS1 EDN1 ACE
23 ischemic colitis 30.0 JAK2 HMOX1 ACE
24 patent ductus arteriosus 1 30.0 NPPB EDN1 ACE
25 microvascular complications of diabetes 3 29.9 REN AGTR1 ACE
26 cardiogenic shock 29.9 NPPB ADM
27 angina pectoris 29.9 NPPB NOS3 EDN1 ACE
28 pheochromocytoma 29.9 REN NPPA NF1 EDN1 CAT ADM
29 acute kidney tubular necrosis 29.8 REN NPPA LCN2 HMOX1 ACE
30 congenital hepatic fibrosis 29.8 PKD1 AGTR1
31 cerebrovascular disease 29.8 REN NPPB NPPA AGTR1 ACE
32 vascular dementia 29.7 SOD1 CAT ACE
33 peripheral artery disease 29.6 NPPB NOS3 HMOX1 EDN1 ACE
34 cardiac arrest 29.5 REN NPPB LCN2 HMOX1 ACE
35 eclampsia 29.5 REN NOS3 EDN1 AGTR1 ACE
36 conn's syndrome 29.4 REN NPPA AGTR1 ACE
37 urinary tract obstruction 29.4 REN LCN2 AGTR1 ACE
38 hypertensive heart disease 29.3 REN NPPB NPPA AGTR1 ACE
39 malignant hypertension 29.2 REN NPPB NPPA EDN1 AGTR1 ADM
40 hyperglycemia 29.2 SOD1 NOS3 CAT AGTR1
41 coronary heart disease 1 29.2 NPPB NOS3 EDN1 AGTR1 ACE
42 arteries, anomalies of 29.1 REN NPPB NOS3 EDN1 AGTR1 ACE
43 ischemia 29.0 SOD1 NPPB NOS3 NOS1 HMOX1 EDN1
44 vascular disease 28.9 SOD1 REN NPPB NOS3 NOS1 HMOX1
45 pulmonary edema 28.9 REN NPPB NPPA NOS3 HMOX1 EDN1
46 end stage renal failure 28.7 SOD1 REN PKD1 NPPB NPPA CAT
47 congestive heart failure 28.7 REN NPPB NPPA NOS3 EDN1 AGTR1
48 stroke, ischemic 28.6 REN NPPB NPPA NOS3 AGTR1 ADM
49 pre-eclampsia 27.8 SOD1 REN NPPA NOS3 HMOX1 EDN1
50 kidney disease 27.6 REN PKD1 NPPB NPPA NOS3 LCN2

Graphical network of the top 20 diseases related to Renovascular Hypertension:



Diseases related to Renovascular Hypertension

Symptoms & Phenotypes for Renovascular Hypertension

MGI Mouse Phenotypes related to Renovascular Hypertension:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ACE ADM AGTR1 EDN1 HMOX1 JAK2
2 homeostasis/metabolism MP:0005376 10.39 ACE ADM AGTR1 CAT EDN1 HMOX1
3 hematopoietic system MP:0005397 10.38 ACE ADM AGTR1 CMA1 HMOX1 JAK2
4 growth/size/body region MP:0005378 10.31 ACE AGTR1 EDN1 HMOX1 JAK2 KRAS
5 immune system MP:0005387 10.31 ACE ADM AGTR1 CMA1 HMOX1 JAK2
6 endocrine/exocrine gland MP:0005379 10.29 ACE ADM EDN1 HMOX1 JAK2 KRAS
7 cellular MP:0005384 10.26 ADM CAT HMOX1 JAK2 KRAS LCN2
8 mortality/aging MP:0010768 10.24 ACE ADM AGTR1 CAT EDN1 HMOX1
9 liver/biliary system MP:0005370 10.14 ACE ADM HMOX1 JAK2 KRAS LCN2
10 adipose tissue MP:0005375 10.09 ACE AGTR1 HMOX1 LCN2 NOS1 NOS3
11 muscle MP:0005369 10.06 ADM EDN1 HMOX1 KRAS NF1 NOS1
12 renal/urinary system MP:0005367 10 ACE ADM AGTR1 EDN1 HMOX1 KRAS
13 neoplasm MP:0002006 9.8 ACE CAT JAK2 KRAS NF1 PKD1
14 reproductive system MP:0005389 9.73 ACE ADM HMOX1 JAK2 KRAS LCN2
15 respiratory system MP:0005388 9.23 ADM HMOX1 JAK2 KRAS NF1 NOS1

Drugs & Therapeutics for Renovascular Hypertension

Drugs for Renovascular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
2
Atorvastatin Approved Phase 3 134523-00-5 60823
3
Amlodipine Approved Phase 3 88150-42-9 2162
4
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
6
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
7
Candesartan Experimental Phase 3 139481-59-7 2541
8 Fibrinolytic Agents Phase 3
9 Anti-Inflammatory Agents Phase 3
10 Anti-Inflammatory Agents, Non-Steroidal Phase 3
11 Antipyretics Phase 3
12 Platelet Aggregation Inhibitors Phase 3
13 Analgesics, Non-Narcotic Phase 3
14 Cyclooxygenase Inhibitors Phase 3
15 Antirheumatic Agents Phase 3
16 Analgesics Phase 3
17 Antihypertensive Agents Phase 3
18 Anticholesteremic Agents Phase 3
19 Angiotensin Receptor Antagonists Phase 3
20 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
21 Hormones Phase 3
22 Hypolipidemic Agents Phase 3
23 Angiotensin II Type 1 Receptor Blockers Phase 3
24 Giapreza Phase 3
25 Amlodipine, atorvastatin drug combination Phase 3
26 calcium channel blockers Phase 3
27 Calcium, Dietary Phase 3
28 Lipid Regulating Agents Phase 3
29 Angiotensinogen Phase 3
30 Antimetabolites Phase 3
31
Lidocaine Approved, Vet_approved 137-58-6 3676
32
Heparin Approved, Investigational 9005-49-6 772 46507594
33
Bevacizumab Approved, Investigational 216974-75-3
34
Sunitinib Approved, Investigational 341031-54-7, 557795-19-4 5329102
35
Cediranib Investigational 288383-20-0 9933475
36 Tezosentan Investigational 180384-57-0
37 Anesthetics, Local
38 Anesthetics
39 Pharmaceutical Solutions
40 calcium heparin
41 Protein Kinase Inhibitors
42 Angiogenesis Inhibitors
43 Angiotensin-Converting Enzyme Inhibitors

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
2 Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection Unknown status NCT00868972 Phase 2, Phase 3
3 Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study. Unknown status NCT02895113 Phase 3 Aspirin
4 Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) Completed NCT00081731 Phase 3 Atacand/HCT, Caduet
5 A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia™ (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA) Terminated NCT01755858 Phase 1, Phase 2 Bendavia;Placebo
6 Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis Completed NCT01840540 Phase 1 Arterial infusion of autologous mesenchymal stem cells
7 Evidence of Procedural Embolism Complicating Renal Artery Stenting Completed NCT00027469 Phase 1
8 Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy Active, not recruiting NCT02266394 Phase 1 Mesenchymal stem cell
9 Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (AMI) Included in the Romanian National Programme of Primary Percutaneous Revascularisation - a Single Center Observational Study Unknown status NCT02388139
10 The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure Unknown status NCT00691730
11 Renal Atherosclerotic Revascularization Evaluation: RAVE Study Completed NCT00127738
12 REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent Completed NCT00631540
13 Assessment of Renal Artery Stenosis and Renovascular Hypertension by Contrast Enhanced Magnetic Resonance Imaging: A Pilot Study Completed NCT00006173
14 PROgression of FIbromuscular LEsions Completed NCT02961868
15 Assessment of Renal and Cervical Artery DysplasIA Completed NCT02884141
16 A Prospective Danish National Registry of Percutaneous Transluminal Renal Angioplasty in Patients With Renovascular Hypertension Recruiting NCT02770066
17 ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension Active, not recruiting NCT01673373
18 Kidney Transplantation and Renal and Myocardial Perfusion Active, not recruiting NCT02960802
19 A Multicenter Registry of Endovascular Therapy for Renal Artery Stenosis in China Not yet recruiting NCT03080519

Search NIH Clinical Center for Renovascular Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fenoldopam
Fenoldopam Mesylate

Cochrane evidence based reviews: hypertension, renovascular

Genetic Tests for Renovascular Hypertension

Anatomical Context for Renovascular Hypertension

MalaCards organs/tissues related to Renovascular Hypertension:

40
Kidney, Testes, Heart, Endothelial, Brain, Liver, Smooth Muscle

Publications for Renovascular Hypertension

Articles related to Renovascular Hypertension:

(show top 50) (show all 4918)
# Title Authors PMID Year
1
Divergences in antihypertensive therapy in special situations in nephrology. 54 61
18425285 2008
2
Pre-operative renal function and selective renal vein renin levels as markers of favourable outcome in renovascular hypertension. 54 61
18062531 2007
3
Pre-operative renal function and selective renal vein renin levels as markers of favourable outcome in renovascular hypertension. 54 61
17489524 2007
4
Assessment of renal artery stenosis severity by pressure gradient measurements. 54 61
17084261 2006
5
Reversible renin-dependent renovascular hypertension successfully treated with percutaneous transluminal renal angioplasty and stenting. 54 61
15876819 2005
6
Renovascular hypertension. 54 61
15695858 2005
7
[Should renal vein catheterization for selective renin determination be performed in patients with suspected renovascular hypertension?]. 54 61
15515466 2004
8
Plasma adrenomedullin concentrations in patients with renovascular or malignant hypertension. 54 61
15284680 2004
9
Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. 54 61
15241786 2004
10
Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives. 54 61
15198480 2004
11
Cyclooxygenase-2 up-regulation in reflux nephropathy. 54 61
14501677 2003
12
Phase-contrast magnetic resonance flow quantification in renal arteries: comparison with 133Xenon washout measurements. 54 61
12511539 2003
13
NT-proANP and BNP in renovascular and in severe and mild essential hypertension. 54 61
12697975 2003
14
On the significance of renal vein renins in renovascular hypertension. 54 61
12011641 2002
15
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. 54 61
12011659 2002
16
Hypertension and renovascular disease: follow-up on 100 renal vein renin samplings. 54 61
11967722 2002
17
Treatment options for renovascular hypertension. 54 61
11934344 2002
18
ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. 54 61
12002704 2002
19
Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. 54 61
11875308 2002
20
The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? 54 61
11791020 2002
21
[Nephrourology and nuclear medicine today]. 54 61
11512405 2001
22
Prostaglandin I(2)/E(2) ratios in unilateral renovascular hypertension of different severities. 54 61
11463755 2001
23
Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. 54 61
11352835 2001
24
[Converting enzyme inhibitors in the diagnosis of secondary arterial hypertension --focus on the captopril test]. 54 61
11301909 2000
25
The pathophysiology of renin release in renovascular hypertension. 54 61
11022891 2000
26
Functional testing: renin studies. 54 61
11022895 2000
27
Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. 54 61
10930193 2000
28
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 54 61
10604545 1999
29
ACE inhibition scintigraphy in the management of hypertension in children. 54 61
10452277 1999
30
Radionuclide renography: a personal approach. 54 61
10321824 1999
31
Short-term modulation of the renin-angiotensin system does not alter plasma adrenomedullin concentration in humans. 54 61
9886897 1998
32
[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension]. 54 61
9813738 1998
33
[Nuclear nephrology]. 54 61
9494337 1997
34
Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. 54 61
9488241 1997
35
Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. 54 61
9486089 1997
36
Plasma endothelin-1 level in patients with renovascular hypertension - does the kidney with stenosis of the renal artery upregulate production of endthelin-1? 54 61
9233908 1997
37
Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. 54 61
8917196 1996
38
Renal extraction of atrial natriuretic peptide in hypertensive patients with or without renal artery stenosis. 54 61
8641732 1996
39
[Comparison of captopril angioscintigraphy and the renin test in diagnosis of renovascular hypertension]. 54 61
8755852 1996
40
Acute blockage of the renin system and differential renal vein renin determinations in the diagnosis of renovascular hypertension. 54 61
8727869 1996
41
Renovascular hypertension in blacks. 54 61
8834702 1996
42
Reversible nephrotic syndrome due to high renin state in renovascular hypertension. 54 61
7731487 1995
43
Effect of chronic ACE inhibition on the diagnostic value of renography for renovascular hypertension: a preliminary report. 54 61
7753462 1995
44
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. 54 61
7713113 1994
45
[Renal ablation by transcatheter renal arterial embolization in the treatment of benign renal disease]. 54 61
9261190 1994
46
Response to the captopril test is dependent on baseline renin profile. 54 61
8021469 1994
47
Captopril-stimulated renal vein renin measurements in the diagnosis of atherosclerotic renovascular hypertension. 54 61
8136101 1994
48
Renin secretion and captopril stimulation in hypertensive renal transplant recipients. 54 61
8178382 1994
49
[Evaluation criteria for captopril-kidney function scintigraphy using 99mTc-MAG3]. 54 61
8295828 1993
50
Scintigraphic evaluation of renovascular hypertension. 54 61
8128734 1993

Variations for Renovascular Hypertension

ClinVar genetic disease variations for Renovascular Hypertension:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PKD1 NM_001009944.3(PKD1):c.9185T>A (p.Val3062Asp)SNV Likely pathogenic 374044 rs1057518856 16:2152398-2152398 16:2102397-2102397

Expression for Renovascular Hypertension

Search GEO for disease gene expression data for Renovascular Hypertension.

Pathways for Renovascular Hypertension

Pathways related to Renovascular Hypertension according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 12.7 KRAS JAK2 HMOX1 EDN1 AGTR1
2
Show member pathways
12.64 NOS3 KRAS JAK2 EDN1 AGTR1
3
Show member pathways
12.49 NOS3 NOS1 KRAS JAK2 EDN1
4
Show member pathways
12.39 NOS3 NOS1 KRAS JAK2 AGTR1
5
Show member pathways
12.35 NOS3 NOS1 LCN2 HMOX1
6
Show member pathways
12.26 NOS3 NF1 KRAS JAK2
7 11.87 NOS3 NOS1 KRAS AGTR1
8 11.71 REN NOS3 HMOX1
9 11.71 NPPA NOS3 HMOX1 EDN1
10 11.65 NOS3 KRAS JAK2 EDN1 AGTR1
11
Show member pathways
11.62 NPPB NPPA NOS3 KRAS EDN1 AGTR1
12 11.55 SOD1 NOS3 JAK2
13 11.53 HMOX1 EDN1 ADM
14 11.5 HMOX1 EDN1 CMA1
15
Show member pathways
11.46 SOD1 NOS3 NOS1
16
Show member pathways
11.46 REN NOS3 CMA1 AGTR1 ACE
17
Show member pathways
11.22 SOD1 NOS3 NOS1 CAT
18 11.19 REN NPPA EDN1 AGTR1 ACE
19 11.07 SOD1 HMOX1 CAT
20 10.71 NOS3 NOS1
21 10.45 NOS3 NOS1

GO Terms for Renovascular Hypertension

Cellular components related to Renovascular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.2 YY1AP1 SOD1 REN PKD1 NPPB NPPA
2 extracellular region GO:0005576 9.96 SOD1 REN NPPB NPPA LCN2 EDN1
3 extracellular space GO:0005615 9.7 SOD1 REN NPPB NPPA LCN2 HMOX1
4 caveola GO:0005901 9.46 NOS3 NOS1 JAK2 HMOX1
5 cell GO:0005623 9.36 SOD1 PKD1 NOS3 NOS1 LCN2 JAK2

Biological processes related to Renovascular Hypertension according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.04 NOS3 NF1 JAK2 HMOX1 ADM
2 positive regulation of apoptotic process GO:0043065 9.99 SOD1 NF1 JAK2 HMOX1 ADM
3 heart development GO:0007507 9.98 PKD1 NF1 EDN1 ADM
4 response to drug GO:0042493 9.93 SOD1 REN LCN2 EDN1 CAT
5 positive regulation of angiogenesis GO:0045766 9.88 NOS3 HMOX1 CMA1 ADM
6 female pregnancy GO:0007565 9.87 NPPA KRAS ADM
7 response to organic substance GO:0010033 9.87 SOD1 REN ADM
8 negative regulation of neuron apoptotic process GO:0043524 9.87 SOD1 KRAS JAK2 HMOX1
9 positive regulation of inflammatory response GO:0050729 9.86 SUCNR1 JAK2 AGTR1
10 regulation of inflammatory response GO:0050727 9.85 JAK2 CMA1 AGTR1
11 liver development GO:0001889 9.85 PKD1 NF1 KRAS
12 response to insulin GO:0032868 9.83 NPPA CAT ADM
13 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 PKD1 JAK2 EDN1 AGTR1 ADM
14 cellular iron ion homeostasis GO:0006879 9.79 SOD1 LCN2 HMOX1
15 response to hydrogen peroxide GO:0042542 9.79 SOD1 HMOX1 CAT
16 response to oxidative stress GO:0006979 9.77 SOD1 LCN2 JAK2 HMOX1 CAT
17 response to heat GO:0009408 9.76 SOD1 NOS3 NOS1
18 response to lipopolysaccharide GO:0032496 9.73 REN NOS3 NOS1 JAK2 EDN1 ADM
19 kidney development GO:0001822 9.72 REN PKD1 CAT AGTR1 ACE
20 positive regulation of renal sodium excretion GO:0035815 9.71 NPPB EDN1
21 positive regulation of urine volume GO:0035810 9.7 NPPB EDN1
22 regulation of synaptic transmission, GABAergic GO:0032228 9.7 NF1 KRAS
23 response to reactive oxygen species GO:0000302 9.7 SOD1 CAT
24 removal of superoxide radicals GO:0019430 9.69 SOD1 NOS3
25 nitric oxide biosynthetic process GO:0006809 9.69 NOS3 NOS1
26 negative regulation of systemic arterial blood pressure GO:0003085 9.68 NPPB NPPA
27 positive regulation of guanylate cyclase activity GO:0031284 9.67 NOS3 NOS1
28 cGMP biosynthetic process GO:0006182 9.67 NPPB NPPA
29 negative regulation of potassium ion transport GO:0043267 9.66 NOS3 NOS1
30 receptor guanylyl cyclase signaling pathway GO:0007168 9.66 NPPB NPPA
31 response to fluid shear stress GO:0034405 9.65 PKD1 NOS3
32 positive regulation of receptor biosynthetic process GO:0010870 9.65 JAK2 EDN1
33 regulation of vasoconstriction GO:0019229 9.65 EDN1 AGTR1 ACE
34 body fluid secretion GO:0007589 9.64 NPPB EDN1
35 regulation of calcium ion transmembrane transport via high voltage-gated calcium channel GO:1902514 9.63 NPPA NOS1
36 negative regulation of hydrolase activity GO:0051346 9.63 NOS3 NOS1
37 positive regulation of heart rate GO:0010460 9.63 NPPA EDN1 ADM
38 arginine catabolic process GO:0006527 9.62 NOS3 NOS1
39 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.61 NOS3 EDN1
40 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.6 AGTR1 ACE
41 angiotensin maturation GO:0002003 9.58 REN CMA1 ACE
42 response to ozone GO:0010193 9.56 EDN1 CAT
43 renin-angiotensin regulation of aldosterone production GO:0002018 9.55 REN AGTR1
44 regulation of angiotensin metabolic process GO:0060177 9.52 SUCNR1 ACE
45 forebrain astrocyte development GO:0021897 9.51 NF1 KRAS
46 response to hypoxia GO:0001666 9.5 NPPA NOS1 NF1 HMOX1 EDN1 CAT
47 smooth muscle hyperplasia GO:0014806 9.49 NOS3 HMOX1
48 regulation of blood vessel diameter GO:0097746 9.46 NPPB NOS3 AGTR1 ACE
49 regulation of blood pressure GO:0008217 9.23 SOD1 REN NPPB NPPA NOS3 HMOX1

Molecular functions related to Renovascular Hypertension according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.56 NPPB NPPA EDN1 ADM
2 NADP binding GO:0050661 9.54 NOS3 NOS1 CAT
3 arginine binding GO:0034618 9.49 NOS3 NOS1
4 NADPH-hemoprotein reductase activity GO:0003958 9.48 NOS3 NOS1
5 hormone receptor binding GO:0051427 9.46 NPPB NPPA
6 cadmium ion binding GO:0046870 9.43 NOS3 NOS1
7 tetrahydrobiopterin binding GO:0034617 9.4 NOS3 NOS1
8 heme binding GO:0020037 9.35 NOS3 NOS1 JAK2 HMOX1 CAT
9 nitric-oxide synthase activity GO:0004517 9.32 NOS3 NOS1
10 signaling receptor binding GO:0005102 9.17 REN NPPB NPPA JAK2 EDN1 CAT
11 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE

Sources for Renovascular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....